Immunoglobulin alpha Fc receptor I (CD89) (CD89)

The Immunoglobulin alpha Fc receptor I (CD89) is a transmembrane glycoprotein expressed primarily on myeloid cells, including neutrophils, monocytes, and macrophages (UniProt P24071). It serves as the primary receptor for the Fc region of Immunoglobulin A (IgA), the most abundant antibody class at mucosal surfaces (Heineke & van Egmond, 2017). Upon binding to IgA-antigen complexes, CD89 associates with the Fc receptor gamma chain to trigger potent effector functions such as phagocytosis, respiratory burst, and antibody-dependent cellular cytotoxicity (ADCC) (Brandsma et al., 2019). In the context of disease, CD89 plays a dual role: it is implicated in the pathogenesis of IgA nephropathy through the formation of nephritogenic IgA-sCD89 complexes, yet it also represents a promising target for cancer immunotherapy by recruiting myeloid cells to kill tumor cells (Aleyd et al., 2015; Boross et al., 2013). Therapeutic strategies currently under investigation include monoclonal antibodies to block its pro-inflammatory activity in autoimmune conditions or bispecific antibodies to redirect its cytotoxic potential against malignancies (Oortwijn et al., 2007). A significant challenge in developing CD89-targeted therapies is the lack of a natural CD89 ortholog in mice, necessitating the use of transgenic animal models for preclinical validation (Heineke & van Egmond, 2017).

Other names

FCARFc alpha receptor IIgA Fc receptorCD89 antigenFcalphaRI

CD89 mediates its effects by binding the Fc portion of IgA1 and IgA2. It signals through the associated FcR gamma-chain (FcRγ) containing immunoreceptor tyrosine-based activation motifs (ITAMs), leading to the activation of Src and Syk family kinases (UniProt P24071). This signaling cascade induces pro-inflammatory responses; however, monomeric IgA binding can also induce inhibitory signaling (ITAMi), providing a mechanism for immune homeostasis (Heineke & van Egmond, 2017).